OmniAb, Inc. (OABI)
US — Healthcare Sector
Automate Your Wheel Strategy on OABI
With Tiblio's Option Bot, you can configure your own wheel strategy including OABI - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol OABI
- Rev/Share 0.2532
- Book/Share 2.5896
- PB 0.6603
- Debt/Equity 0.0822
- CurrentRatio 4.6969
- ROIC -0.2132
- MktCap 209192850.0
- FreeCF/Share -0.3892
- PFCF -5.0892
- PE -2.9477
- Debt/Assets 0.0734
- DivYield 0
- ROE -0.2137
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 4
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
About OmniAb, Inc. (OABI)
- IPO Date 2021-09-30
- Website https://www.omniab.com
- Industry Biotechnology
- CEO Mr. Matthew W. Foehr
- Employees 114
OmniAb, Inc., a biotechnology company, provides therapeutic antibody discovery technologies in the United States. The company's discovery platform provides industry partners access to the diverse antibody repertoires and screening technologies to enable discovery of next-generation therapeutics. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTaur that features unique structural attributes of cow antibodies for complex targets. The company was founded in 2012 and is headquartered in Emeryville, California.